G1 Therapeutics Inc
NASDAQ:GTHX
Intrinsic Value
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. [ Read More ]
The intrinsic value of one GTHX stock under the Base Case scenario is 14.86 USD. Compared to the current market price of 4.11 USD, G1 Therapeutics Inc is Undervalued by 72%.
Valuation Backtest
G1 Therapeutics Inc
Run backtest to discover the historical profit from buying and selling GTHX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
G1 Therapeutics Inc
Current Assets | 126.1m |
Cash & Short-Term Investments | 94.3m |
Receivables | 9.3m |
Other Current Assets | 22.5m |
Non-Current Assets | 7m |
PP&E | 6.8m |
Other Non-Current Assets | 200k |
Current Liabilities | 33.7m |
Accounts Payable | 7.3m |
Accrued Liabilities | 24.2m |
Other Current Liabilities | 2.2m |
Non-Current Liabilities | 56.4m |
Long-Term Debt | 51.2m |
Other Non-Current Liabilities | 5.2m |
Earnings Waterfall
G1 Therapeutics Inc
Revenue
|
82.5m
USD
|
Cost of Revenue
|
-7.2m
USD
|
Gross Profit
|
75.3m
USD
|
Operating Expenses
|
-114.8m
USD
|
Operating Income
|
-39.5m
USD
|
Other Expenses
|
-8.4m
USD
|
Net Income
|
-48m
USD
|
Free Cash Flow Analysis
G1 Therapeutics Inc
What is Free Cash Flow?
GTHX Profitability Score
Profitability Due Diligence
G1 Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
G1 Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
GTHX Solvency Score
Solvency Due Diligence
G1 Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
G1 Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GTHX Price Targets Summary
G1 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GTHX is 8.67 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.
Ownership
GTHX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GTHX Price
G1 Therapeutics Inc
Average Annual Return | -19.12% |
Standard Deviation of Annual Returns | 41.29% |
Max Drawdown | -97% |
Market Capitalization | 212.9m USD |
Shares Outstanding | 52 200 000 |
Percentage of Shares Shorted | 5.33% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one GTHX stock under the Base Case scenario is 14.86 USD.
Compared to the current market price of 4.11 USD, G1 Therapeutics Inc is Undervalued by 72%.